Search over 3,000 reports

    Sarcopenia - Market Insights, Epidemiology and Market Forecast - 2025

    Sarcopenia - Market Insights, Epidemiology and Market Forecast - 2025
    Date: Dec, 2017
    Type: Pharmaceutical Industry Report
    Pages: 70
    Geography: Global
    Delivery Timeline: 5 Business Days
    SKU: DIMI0004A
    DelveInsight's "Sarcopenia - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Sarcopenia for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Sarcopenia . It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Sarcopenia for 7 major markets.

    The market outlook also provides understanding of country specific revenue and share by analyzing performance of the current therapies and thorough potential uptake of new products. Additionally, the Report highlights the frontrunners, the drivers and barriers for the Sarcopenia market, as well as treatment algorithm, current treatments & advancements are included.The chapters including marketed products highlights the advantages and disadvantages associated with therapies associated with Sarcopenia , providing an in-depth analysis of emerging therapies which will create an impact through their launch.

    According to DelveInsight, the forecasted patient population of Sarcopenia for the year 2025 will be XX, increasing at a CAGR of XX% from 2015 to 2025 and the Sarcopenia 7MM market size is estimated to be USD XX by 2025.The DelveInsight Report will help in enhanced understanding of the Sarcopenia market from inside out, with transparency into the calculated patient forecasting data and estimated market size.

    Key Coverage

    • Understanding historical and forecasted epidemiological data for Sarcopenia covering 7MM from 2015-2025.
    • Segment level epidemiology and market split for Sarcopenia .
    • The thorough assessment of competitors, market, current trends & treatments along with upcoming treatments for Sarcopenia .
    • The Report also covers the market size for 7MM (United States, EU 5 (Germany, Spain, Italy, France and United Kingdom) and Japan) from 2015-2025 and detailed historical and forecasted Sarcopenia market trends.
    • Thorough market distribution based on market share for Sarcopenia .

    Reasons to buy

    • The report will help in developing business strategies by understanding trends shaping and driving the Sarcopenia market.
    • To understand the future market competition in the Sarcopenia market and Insightful review of the key market drivers and barriers.
    • Organize sales and marketing efforts by identifying the best opportunities for Sarcopenia in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
    • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.

    1. Report Introduction
    2. Sarcopenia Market Overview at a Glance
    2.1. Total Market Share Distribution of Sarcopenia for 7 MM in 2016
    2.2. Total Market Share Distribution of Sarcopenia for 7 MM in 2025
    3. Sarcopenia
    3.1.1. Overview
    3.1.2. Symptoms
    3.1.3. Pathophysiology
    3.1.4. Staging
    3.1.5. Diagnosis
    3.1.6. Treatment
    4. Epidemiology and Patient Population
    4.1.1. United States
    4.1.1.1. Diagnosed Cases of Sarcopenia in United States
    4.1.2. Germany
    4.1.2.1. Diagnosed Cases of Sarcopenia in Germany
    4.1.3. France
    4.1.3.1. Diagnosed Cases of Sarcopenia in France
    4.1.4. Italy
    4.1.4.1. Diagnosed Cases of Sarcopenia in Italy
    4.1.5. Spain
    4.1.5.1. Diagnosed Cases of Sarcopenia in Spain
    4.1.6. United Kingdom
    4.1.6.1. Diagnosed Cases of Sarcopenia in United Kingdom
    5. Treatment Algorithm
    5.1.1. Treatment Guidelines/Practices
    6. Marketed Drugs for Sarcopenia
    6.1. Drug 1: Company A
    6.1.1. Drug Description
    6.1.2. Mechanism of Action
    6.1.3. Regulatory Milestones
    6.1.4. Advantages & Disadvantages
    6.1.5. Safety and Efficacy
    6.1.6. Product Profile
    6.1.7. Patent Status
    6.2. Drug 2: Company B
    6.2.1. Drug Description
    6.2.2. Mechanism of Action
    6.2.3. Regulatory Milestones
    6.2.4. Advantages & Disadvantages
    6.2.5. Safety and Efficacy
    6.2.6. Product Profile
    6.2.7. Patent Status
    7. Emerging Therapies
    7.1. Drug 3: Company C
    7.1.1. Description
    7.1.2. Regulatory Milestones
    7.1.3. Advantages & Disadvantages
    7.1.4. Product Profile
    7.1.5. Launch Date
    7.1.6. Clinical Development
    7.1.7. Clinical Pipeline Activity
    7.1.8. Ongoing Trials Information
    7.1.9. Clinical Trial by Phase
    7.2. Drug 4: Company B
    7.2.1. Description
    7.2.2. Regulatory Milestones
    7.2.3. Advantages & Disadvantages
    7.2.4. Product Profile
    7.2.5. Launch Date
    7.2.6. Clinical Development
    7.2.7. Clinical Pipeline Activity
    7.2.8. Ongoing Trials Information
    7.2.9. Clinical Trial by Phase
    8. Overview of Total Sarcopenia Market (2016 & 2025)
    9. Sarcopenia : Country-Wise Market Analysis
    9.1. United States
    9.1.1. Historical Market Size (2015-2016)
    9.1.2. Forecasted Market Size (2017-2025)
    9.2. Germany Market Size
    9.2.1. Historical Market Size (2015-2016)
    9.2.2. Forecasted Market Size (2017-2025)
    9.3. France Market Size
    9.3.1. Historical Market Size (2015-2016)
    9.3.2. Forecasted Market Size (2017-2025)
    9.4. United Kingdom Market Size
    9.4.1. Historical Market Size (2015-2016)
    9.4.2. Forecasted Market Size (2017-2025)
    9.5. Spain Market Size
    9.5.1. Historical Market Size (2015-2016)
    9.5.2. Forecasted Market Size (2017-2025)
    9.6. Italy Market Size
    9.6.1. Historical Market Size (2015-2016)
    9.6.2. Forecasted Market Size (2017-2025)
    9.7. Japan Market Size
    9.7.1. Historical Market Size (2015-2016)
    9.7.2. Forecasted Market Size (2017-2025)
    10. Market Drivers
    11. Market Restraints
    12. Appendix
    13. Report Methodology
    14. Consulting Services
    15. Disclaimer
    16. About DelveInsight
    Table 1: Diagnosed Cases Sarcopenia in United States (2015-2025)
    Table 2: Diagnosed Cases Sarcopenia in Germany (2015-2025)
    Table 3: Diagnosed Cases Sarcopenia in France (2015-2025)
    Table 4: Diagnosed Cases Sarcopenia in United Kingdom (2015-2025)
    Table 5: Diagnosed Cases Sarcopenia in Spain (2015-2025)
    Table 6: Diagnosed Cases Sarcopenia in Italy (2015-2025)
    Table 7: Diagnosed Cases Sarcopenia in Japan (2015-2025)
    Table 8: List of Marketed Drugs for Sarcopenia
    Table 9: List of Pipeline Phase III Drugs for Sarcopenia
    Table 10: Drug 1, Clinical Trials by Zone, 2017
    Table 11: Clinical Trials by Trial status, 2017
    Table 12: Drug 2, Clinical Trials by Zone, 2017
    Table 13: Clinical Trials by Trial status, 2017
    Table 14: Drug 3, Clinical Trials by Zone, 2017
    Table 15: Clinical Trials by Trial status, 2017
    Table 16: United States Market Size of Sarcopenia in USD, Million (2015-2025)
    Table 17: Germany Market Size of Sarcopenia in USD, Million (2015-2025)
    Table 18: France Market Size of Sarcopenia in USD, Million (2015-2025)
    Table 19: United Kingdom Market Size of Sarcopenia in USD, Million (2015-2025)
    Table 20: Spain Market Size of Sarcopenia in USD, Million (2015-2025)
    Table 21: Italy Market Size of Sarcopenia in USD, Million (2015-2025)
    Table 22: Japan Market Size of Sarcopenia in USD, Million (2015-2025)
    Figure 1: Diagnosed Cases Sarcopenia in United States (2015-2025)
    Figure 2: Diagnosed Cases Sarcopenia in Germany (2015-2025)
    Figure 3: Diagnosed Cases Sarcopenia in France (2015-2025)
    Figure 4: Diagnosed Cases Sarcopenia in United Kingdom (2015-2025)
    Figure 5: Diagnosed Cases Sarcopenia in Spain (2015-2025)
    Figure 6: Diagnosed Cases Sarcopenia in Italy (2015-2025)
    Figure 7: Diagnosed Cases Sarcopenia in Japan (2015-2025)
    Figure 8: List of Marketed Drugs for Sarcopenia
    Figure 9: List of Pipeline Phase III Drugs for Sarcopenia
    Figure 10: Drug 1, Clinical Trials by Zone (%), 2017
    Figure 11: Clinical Trials by Trial status, 2017
    Figure 12: Drug 2, Clinical Trials by Zone (%), 2017
    Figure 13: Clinical Trials by Trial status, 2017
    Figure 14: Drug 3, Clinical Trials by Zone (%), 2017
    Figure 15: Clinical Trials by Trial status, 2017
    Figure 16: United States Market Size of Sarcopenia in USD, Million (2015-2025)
    Figure 17: Germany Market Size of Sarcopenia in USD, Million (2015-2025)
    Figure 18: France Market Size of Sarcopenia in USD, Million (2015-2025)
    Figure 19: United Kingdom Market Size of Sarcopenia in USD, Million (2015-2025)
    Figure 20: Spain Market Size of Sarcopenia in USD, Million (2015-2025)
    Figure 21: Italy Market Size of Sarcopenia in USD, Million (2015-2025)
    Figure 22: Japan Market Size of Sarcopenia in USD, Million (2015-2025)
    Sarcopenia Market (7MM)

    Sarcopenia Market forecasting

    Sarcopenia Sales forecasting

    Sarcopenia Market segments

    Sarcopenia Epidemiology

    Sarcopenia Pipeline products and technologies

    Sarcopenia Competitive landscape

    Sarcopenia SWOT analysis

    Sarcopenia Market Driver's and barriers

    Sarcopenia Key Companies and Funding



    • Single User License
      (20% Off)
      $5,750.00
    • Site License
      (30% Off)
      $11,500.00
    • Global License
      (40% Off)
      $17,250.00

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap